BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 29378728)

  • 21. Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome.
    Chaput F; Amer R; Baglivo E; Touitou V; Kozyreff A; Bron D; Bodaghi B; LeHoang P; Bergstrom C; Grossniklaus HE; Chan CC; Pe'er J; Caspers LE
    Ocul Immunol Inflamm; 2017 Oct; 25(5):639-648. PubMed ID: 27002464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.
    Hashida N; Nakai K; Saitoh N; Nishida K
    Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):687-93. PubMed ID: 24549401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial.
    Jahnke K; Korfel A; Komm J; Bechrakis NE; Stein H; Thiel E; Coupland SE
    Graefes Arch Clin Exp Ophthalmol; 2006 Jun; 244(6):663-9. PubMed ID: 16228920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma.
    Zhou N; Xu X; Liu Y; Wang Y; Wei W
    Eye (Lond); 2022 Jul; 36(7):1448-1455. PubMed ID: 34211136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serial changes in the aqueous IL-10 level after intravitreal methotrexate injection as an indicator of primary vitreoretinal lymphoma recurrence.
    Park YG; Park WK; Kim RY; Kim M; Park YH
    Sci Rep; 2020 Oct; 10(1):15992. PubMed ID: 33009434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center.
    Giuffrè C; Cicinelli MV; Marchese A; Modorati GM; Brambati M; Ferreri AJM; Calimeri T; Ponzoni M; Bandello F; Miserocchi E
    Ocul Immunol Inflamm; 2021 Apr; 29(3):472-478. PubMed ID: 32845738
    [No Abstract]   [Full Text] [Related]  

  • 27. Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma.
    de la Fuente MI; Alderuccio JP; Reis IM; Omuro A; Markoe A; Echegaray JJ; Davis JL; Harbour JW; Lossos IS
    Am J Hematol; 2019 Apr; 94(4):455-460. PubMed ID: 30663807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
    Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
    Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.
    Kaburaki T; Taoka K
    Jpn J Ophthalmol; 2023 Jul; 67(4):363-381. PubMed ID: 37209195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical review: treatment of vitreoretinal lymphoma.
    Pe'er J; Hochberg FH; Foster CS
    Ocul Immunol Inflamm; 2009; 17(5):299-306. PubMed ID: 19831557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience.
    Habot-Wilner Z; Frenkel S; Pe'er J
    Br J Haematol; 2021 Jul; 194(1):92-100. PubMed ID: 33900619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. INTRAVITREAL MELPHALAN INJECTION AS A SECOND-LINE LOCAL THERAPY IN VITREORETINAL LYMPHOMA: Case Series.
    Guneri Beser B; Demirci H
    Retina; 2024 Feb; 44(2):353-359. PubMed ID: 37883576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study.
    Lam M; Touitou V; Choquet S; Cassoux N; Ghesquières H; Kodjikian L; Schmitt A; Gattoussi S; Tabouret É; Sampo M; Blonski M; Angioi-Duprez K; Houot R; Mouriaux F; Gyan E; Le Lez ML; Moles MP; Croisé F; Chauchet A; Schwartz C; Ahle G; Meyer L; Gressin R; Chiquet C; Oberic L; Ollé P; Marolleau JP; Jany B; Tempescul A; Cochener B; Damaj G; Quintyn JC; Moluçon-Chabrot C; Rousseau E; Franciane P; Schneider C; Massé H; Tamburini-Bonnefoy J; Brézin A; Fornecker LM; Ballonzoli L; Le Garff-Tavernier M; Hoang-Xuan K; Bodaghi B; Soussain C; Houillier C
    Am J Hematol; 2021 Jul; 96(7):823-833. PubMed ID: 33864703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary Vitreoretinal Lymphoma in HIV Infection.
    Steffen J; Coupland SE; Smith JR
    Ocul Immunol Inflamm; 2021 Apr; 29(3):621-627. PubMed ID: 32453669
    [No Abstract]   [Full Text] [Related]  

  • 35. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.
    Smith JR; Rosenbaum JT; Wilson DJ; Doolittle ND; Siegal T; Neuwelt EA; Pe'er J
    Ophthalmology; 2002 Sep; 109(9):1709-16. PubMed ID: 12208721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary vitreoretinal natural killer/T-cell lymphoma with breast involvement: A case report and review of the literature.
    Gao S; Zhou Y; Jin X; Lin Z; Zhong Y; Shen X
    Surv Ophthalmol; 2019; 64(2):225-232. PubMed ID: 30321569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma.
    Akiyama H; Takase H; Kubo F; Miki T; Yamamoto M; Tomita M; Mochizuki M; Miura O; Arai A
    Cancer Sci; 2016 Oct; 107(10):1458-1464. PubMed ID: 27412324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma.
    Larkin KL; Saboo US; Comer GM; Forooghian F; Mackensen F; Merrill P; Sen HN; Singh A; Essex RW; Lake S; Lim LL; Vasconcelos-Santos DV; Foster CS; Wilson DJ; Smith JR
    Br J Ophthalmol; 2014 Jan; 98(1):99-103. PubMed ID: 24158837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
    Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
    Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of intravitreal rituximab and methotrexate in vitreoretinal lymphoma.
    Rahhal-Ortuño M; Udaondo-Mirete P; Fernández-Santodomingo AS; Díaz-Llopis M
    Eur J Ophthalmol; 2022 Jan; 32(1):NP199-NP202. PubMed ID: 32985253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.